Clinical Trials Logo

B-Cell Lymphoma clinical trials

View clinical trials related to B-Cell Lymphoma.

Filter by:

NCT ID: NCT05757700 Recruiting - B-Cell Lymphoma Clinical Trials

Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma

Start date: February 23, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this research is to evaluate if study therapy, 19(T2)28z1xx TRAC-chimeric antigen receptor (CAR) T cells, may be an effective treatment for people with relapsed/refractory B-cell lymphoma. Researchers will also evaluate if this study therapy is safe, and to look for the highest dose that causes few or mild side effects in participants.

NCT ID: NCT05755828 Recruiting - B-cell Lymphoma Clinical Trials

Clinical Study of Autologous Stem Cell Transplantation + Anti-CD19 CAR T Cells for B-cell Lymphoma

Start date: December 1, 2022
Phase: Phase 2
Study type: Interventional

To evaluate the CR rate of B-NHL subjects who achieved PR at intermediate assessment after first-line chemotherapy treated with autologous stem cell transplantation + Anti-CD19 CAR T cells.

NCT ID: NCT05739227 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic Malignancies

Start date: March 1, 2023
Phase: Early Phase 1
Study type: Interventional

This is an open label, single-arm, Phase I study to evaluate the efficacy and safety of allogenic CD19-CAR-NK cells in subjects with refractory or relapsed B-cell hematologic malignancies. A leukapheresis procedure will be performed to manufacture Anti-CD19 chimeric antigen receptor (CAR) modified NK cells. Prior to allogenic CD19-CAR-NK cells infusion subjects will receive lymphodepleting therapy with fludarabine, cyclophosphamide and etoposide.

NCT ID: NCT05691153 Recruiting - B Cell Lymphoma Clinical Trials

ThisCART19A for B-NHL Relapsed After Auto-CAR T

Start date: December 1, 2022
Phase: Phase 1
Study type: Interventional

This is a phase 1, single-center, dose selection study to evaluate the efficacy, safety, and pharmacokinetics of ThisCART19A (allogeneic CAR-T targeting CD19) in patients with Auto-CAR T relapsed B-cell non-Hodgkin's lymphoma.

NCT ID: NCT05653271 Recruiting - Follicular Lymphoma Clinical Trials

ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

Start date: January 21, 2023
Phase: Phase 1
Study type: Interventional

ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of CD20-expressing B-cell malignancies. The ACE1831-001 study is an open-label, Phase I, first-in-human (FIH) study that aims to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, and efficacy of ACE1831 in patients with CD20-expressing Non-Hodgkin lymphoma.

NCT ID: NCT05643742 Recruiting - Clinical trials for Mantle Cell Lymphoma

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

Start date: March 10, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX112™ in subjects with relapsed or refractory B-cell malignancies.

NCT ID: NCT05615636 Recruiting - Hodgkin Lymphoma Clinical Trials

A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

Start date: April 28, 2023
Phase: Phase 2
Study type: Interventional

To learn if giving mosunetuzumab in combination with polatuzumab vedotin, tafasitamab, and lenalidomide can help to control relapsed/refractory FL and DLBCL.

NCT ID: NCT05590221 Recruiting - B-cell Lymphoma Clinical Trials

Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma

Start date: January 3, 2023
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to estimate the efficacy of Relmacabtagene Autoleucel in participants with high-risk large B-cell lymphoma.

NCT ID: NCT05495828 Recruiting - B-cell Lymphoma Clinical Trials

Orelabrutinib Therapy in Patients With r/r B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase Inhibitors

Start date: November 10, 2023
Phase:
Study type: Observational

To evaluate the safety and effecacy of Orelabrutinib therapy in patients with relapsed or refractory B-cell lymphoma (including R /rCLL/SLL and R /rMCL) who are intolerant to ibrutinib/zanubrutinib or other BTK inhibitors

NCT ID: NCT05487651 Recruiting - B-cell Lymphoma Clinical Trials

Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies

ANCHOR2
Start date: October 1, 2022
Phase: Phase 1
Study type: Interventional

This study is a multi-center study to evaluate the safety of KUR-502 in subjects with refractory/relapsed B-cell NHL or leukemia (ALL or CLL).